QIAGEN NV Q3 FY2024 earnings call

Thierry Bernard noted that the teams exceeded targets for sales and adjusted earnings. Key initiatives included strong performance of QIAstat with 40% CER growth and multiple FDA clearances, progress in the QIAcuity digital PCR system with new assays and clinical placements. Adjusted operating income margin improved by 3% to 29.6%. Free cash flow for the first nine months of 2024 increased by 73% to $364 million. The company achieved several important product launches and key milestones, positioning QIAGEN strongly for future growth towards the 2028 commitment.

In the third quarter, QIAGEN achieved $502 million in sales, representing a 6% growth at constant exchange rate, which exceeded the outlook of at least $495 million at CER. Growth excluding the NeuMoDx franchise was also 6% CER. The Diagnostic Solutions product group saw a 10% growth at constant exchange rate. Consumables and related revenues grew 8% CER over Q3 2023 and contributed 89% to sales. Instrument sales declined 9% CER due to cautious customer spending. QIAstat had a 40% CER sales growth with more than 150 placements of instruments in the third quarter. The QIAcuity digital PCR system added 100 new validated assays and made progress in clinical applications.

QIAGEN reaffirmed the full year net sales outlook of at least $1.985 billion at constant exchange rate. The adjusted EPS target was increased to at least $2.19 at constant exchange rate. For the fourth quarter, the net sales outlook is at least $520 million at constant exchange rate, an increase of about 2% CER from Q3 2023, with underlying 3% CER growth over Q3 2023 in the second half.

The challenging macro environment, cautious customer spending on instruments, potential impact of currency fluctuations, and uncertainties related to regulatory changes and market competition are risks that need to be considered.

Q: Patrick Donnelly asked about the sustainability of QuantiFERON's growth.

A: Thierry Bernard stated that the main drivers are the conversion of the skin test market, the partnership with DiaSorin, and the conversion of countries to have latent TB testing in guidelines.

Q: Odysseas Manesiotis inquired about QIAstat placements.

A: Thierry Bernard said Q3 had over 150 placements, with a 50% split between placements and capital sales, and QIAstat is competitive in the US market with multiple panels.

Q: Matt Sykes asked about the portfolio mix for growth.

A: Thierry Bernard mentioned QIAstat, QuantiFERON, QIAcuity, and QDI as growth pillars with specific targets.

Q: Doug Schenkel asked about share buyback and margin trajectory.

A: Thierry Bernard and Roland Sackers said the company is active on buyback and M&A, and margin improvement will continue with the wind down of NeuMoDx and process optimization.

Q: Aisyah Noor asked about the QDI business and QuantiFERON partnerships.

A: Thierry Bernard said the shift of QDI to subscription is a trend, and QuantiFERON is open to new partners with criteria such as installed base and willingness to invest.

Q: Michael Ryskin asked about sample prep and NeuMoDx.

A: Thierry Bernard said sample prep has new system launches and NeuMoDx will have no revenues in the second half of 2025.

Q: Casey Woodring asked about instrument growth.

A: Roland Sackers said the fourth quarter is expected to have slightly better sequential growth in instrumentation.

Q: Andrew Brackmann asked about tariffs and business impact.

A: Thierry Bernard and Roland Sackers said the company's global presence is a strength, and details on tariffs and tax policies are premature.